Serum HER-2 extracellular domain: Relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients

Saghatchian, M.; Guepratte, S.; Hacène, K.; Neumann, Rainer; Floiras, J.-L.; Pichon, M.

doi:10.5301/jbm.2008.1233

Cited by 21 publications

(16 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of our prospective study are in agreement with two retrospective studies [28,24] that showed a shorter DFS in patients with elevated serum HER2 ECD levels. The adverse prognostic value of elevated HER2 ECD levels in early breast cancer could reflect the presence of micrometastases or high HER2 cleavage and shedding with the production of truncated cell-associated fragments that contain the signaling kinase domain activated in absence of the ECD [29].…”

Section: Discussionsupporting

confidence: 82%

See 1 more Smart Citation

Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival

et al. 2008

View full text Add to dashboard Cite

Background:We explored the correlation between serum human epidermal growth factor receptor-2 (HER2) extracellular domain (ECD) and tissue HER2 status, their relationship with clinicopathological parameters and their impact on disease-free survival (DFS) and overall survival in early breast cancer patients. High serum HER2 ECD levels ( ‡15 ng/ml) were reported in 23 patients (9.0%) and HER2-positive status in tumor tissue was observed in 42 patients (16.4%) with a concordance of 87.1%. High HER2 ECD levels were significantly associated with high histological grade (P = 0.003), stage III (P = 0.008), lymph node involvment (P = 0.035) and negativity of both estrogen (P = 0.016) and progesterone (P = 0.007) receptors. At multivariate analysis, high serum HER2 ECD levels were a significant independent prognostic factor of worse DFS (P = 0.009).Conclusions: A statistically significant association was observed between high serum HER2 ECD levels and worse DFS in early breast cancer patients.

show abstract

Section: Discussionsupporting

confidence: 82%

“…The percentage of elevated serum levels of HER2 ECD are extremely variable in early breast cancer patients at the time of diagnosis. In our study, high HER2 ECD levels were observed in 9.0% of early breast cancer patients, similar to the results reported by other authors [22][23][24].…”

Section: Discussionsupporting

confidence: 81%

Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Studies have shown that serum HER2 levels, prior to treatment, positively correlate with tumor size, number of positive lymph nodes and histological scores [25]. In fact, serum HER2 levels were a better indicator for stage IV breast cancer than were IHC scores [26].…”

Section: Her2mentioning

confidence: 99%

“…In fact, serum HER2 levels were a better indicator for stage IV breast cancer than were IHC scores [26]. Serum HER2 levels were also an effective prognostic indicator for metastasis-free and disease-specific survival after treatment cessation [25]. FACTT was used to detect and quantify HER2 in both rodent and human blood [12].…”

Section: Her2mentioning

confidence: 99%

Non-invasive, ultra-sensitive, high-throughput assays to quantify rare biomarkers in the blood

Freudenberg

Bembas

Greene

et al. 2008

Methods

View full text Add to dashboard Cite

Many diseases are easier to treat and control when detected at an early stage of disease progression. Often, disease-related antigens or biomarkers are shed from the primary site and present in the blood. Unfortunately, there are very few tests capable of detecting these rare biomarkers in the blood. A blood test would be very useful to diagnose the disease earlier, monitor effectiveness of treatments, predict recurrence, and monitor recurrence. There is certainly a need to develop assays that are ultrasensitive, non-invasive and high-throughput. Here we describe several highly sensitive immunological assays we have developed to detect rare serum antigens. Initially we created an assay named immunodetection amplified by T7 RNA polymerase (IDAT). To enhance the effectiveness and streamline the procedure, this assay was amended to the facile amplification system termed fluorescent amplification catalyzed by T7 polymerase technique (FACTT). These assays have been used to analyze the tumor antigen HER2 and the prion protein PrP Sc . They can also be applied to other tumor markers or antigens from a variety of diseases such as cardiovascular disease, rheumatoid arthritis, Alzheimer's disease, Parkinson's disease, and hepatitis. These tests are not limited to testing only serum, but may also be applicable to detecting biomarkers in tissue, saliva, urine, cerebrospinal fluid, etc. Clearly, the FACTT-based technology represents an important step in the detection of rare molecules in fluids or tissues for a variety of diseases.

show abstract

“…En revanche, une valeur sérique normale ne peut pas être corrélée à une absence de surexpression de c-erb B2 par la tumeur. L'élévation de l'ECD dans les cancers précoces témoigne de l'agressivité de la tumeur et paraît associée à une augmentation du risque de métastases viscé-rales et de cancers mammaires controlatéraux [47]. Une augmentation des valeurs sériques d'ECD a un impact péjo-ratif sur la survie globale et sans récidive.…”

Section: C-erb B2unclassified

Marqueurs protéiques circulants et cancer du sein

Mathelin

Koehl

Rio

2006

Gynécologie Obstétrique & Fertilité

View full text Add to dashboard Cite

Serum HER-2 extracellular domain: Relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients

Cited by 21 publications

References 13 publications

Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival

Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival

Non-invasive, ultra-sensitive, high-throughput assays to quantify rare biomarkers in the blood

Marqueurs protéiques circulants et cancer du sein

Contact Info

Product

Resources

About